Methylzyme focuses on the development of epigenetic modulators to treat solid tumors including breast cancer and melanoma by boosting antitumor immune responses. One co-founder, Dr. Qin Yan from Yale, is an expert of KDM5 biology and drug development. Dr. Yan found that KDM5B loss induces anti-tumor immune response in a demethylase-independent manner. He has developed KDM5 degraders to eliminate KDM5 enzymes with the other co-founder Dr. Jian Jin from Mount Sinai. Dr. Jin is a world-leader of drug development, especially epigenetic drugs. He is a co-founder of Cullgen and has advanced 5 compounds into clincial trials. He is an inventor of Daprodustat, an anemia drug approved in the US and Japan. Methylzyme is currently supported by a 2022 Blavatnik Award and is seeking for series A funding to advance the compound series to IND filing in two years.